The study was a follow-up of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients undergoing major orthopedic surgery showed 25% reduction in the incidence of VTE and all-cause death by using ultra-low-molecular-weight heparin Semuloparin when compared to the commonly used therapy drug enoxaparin (a low-molecular-weight heparin).
The meta-analysis study reported results from patients recruited in three orthopedic surgery studies in hip replacement (Save Hip), hip fracture (Save Hip-FRA) and knee replacement (Save Knee).
The Save program is supported by sanofi-aventis, producer of semuloparin.
The objective of the three studies was to assess once-daily preventative treatment with Semuloparin (20mg) compared to enoxaparin (40mg daily in hip, and 30mg twice-daily for knee) for seven to 10 days.
Semuloparin’s benefit-to-risk profile in cancer is currently being investigated in two ongoing phase three clinical studies. Save Onco evaluates Semuloparin in patients with cancer undergoing chemotherapy. Save Abdo assesses the benefits of Semuloparin in major abdominal surgery, mainly cancer surgery.